title: TLI in refractory chronic GVHD.
abstract: Refractory chronic GVHD (cGVHD) remains a major cause of morbidity after transplantation. Many drugs are used but there is no consensus on the standard of care. We investigated the efficacy of TLI in corticosteroid-refractory cGVHD. We analyzed retrospectively 31 patients receiving one or more TLI session for refractory cGVHD from 2000 to 2007. The main objective was to evaluate the response rate after TLI. Decreased corticosteroid doses and/or discontinued immunosuppressive agents were considered to be surrogate markers of response. All but one patient presented with severe cGVHD at the time of TLI. The median number of previous immunosuppressive treatment lines was 3 (range: 2-4). Fourteen patients (45%) achieved an objective response after TLI and 8 (25%) were cGVHD free at long-term follow-up. In all, 5 (29%) of the 17 nonresponsive patients did not show the features of progressive cGVHD and could decrease the amount of immunosuppressive drugs taken. Response after TLI significantly improved 5-year GVHD-related mortality (14% vs 42%, P=0.038) but not OS (58%vs 64% P=0.27). Regarding the promising response rate in this heavily pretreated population, we reasoned that TLI could be an alternative treatment for corticosteroid-refractory cGVHD.
authors.affiliation: Department of Hematology, Transplantation Program, Institut Paoli Calmettes, Marseille, France.
authors.forename: R
authors.initials: R
authors.lastname: Devillier
authors.forename: L
authors.initials: L
authors.lastname: Castagna
authors.forename: L
authors.initials: L
authors.lastname: Gonzague
authors.forename: J
authors.initials: J
authors.lastname: El-Cheikh
authors.forename: S
authors.initials: S
authors.lastname: Fürst
authors.forename: C
authors.initials: C
authors.lastname: Faucher
authors.forename: R
authors.initials: R
authors.lastname: Michel
authors.forename: D
authors.initials: D
authors.lastname: Blaise
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D064591:Allografts; D002908:Chronic Disease; D018572:Disease-Free Survival; D004351:Drug Resistance / Q000187:drug effects / Q000528:radiation effects; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000401:mortality / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000401:mortality / Q000628:therapy; D033581:Stem Cell Transplantation; D015996:Survival Rate
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents